Pfizer Reports Positive Phase 3 Results for LITFULO in Nonsegmental Vitiligo

Pfizer Inc. announced positive topline results from two Phase 3 trials (TRANQUILLO and TRANQUILLO 2) evaluating LITFULO (ritlecitinib) once daily for nonsegmental vitiligo (NSV). The trials showed significant, clinically meaningful improvements over placebo in facial and total body repigmentation, reinforcing LITFULO's potential as a systemic treatment option for patients with varying disease severity.